Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113542 · ClinicalTrials.gov registry record · Phase 2
A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00113542 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 10 participants.
The verdict
NCT00113542, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Psoriasis is a common skin disease affecting an estimated 2.6% of the US population. It is a chronic, recurrent condition for which there is no cure, but there are ways to control it. Psoriasis is characterized by epidermal hyperplasia (abnormal increase in the number of normal cells of the outer layer of the skin). Tetrathiomolybdate (TM), a copper chelator (a drug that removes copper from the bloodstream) was first created to treat Wilson's disease, a disorder caused by too much copper in the blood. Studies in animals have since shown that TM may also prevent the formation of new blood vessels and may also block the key components of inflammation (swelling, redness, and pain) caused by psoriasis. TM is not approved by the FDA for any use yet. It is an investigational drug used for clinical research. We propose to test whether a new treatment with TM can in fact improve or stabilize psoriasis.
Interventions
- DRUG Tetrathiomolybdate (TM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113542
The ClinicalTrials.gov registry entry for NCT00113542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrathiomolybdate (TM) is the first listed.
NCT00113542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113542 about?
NCT00113542 is a clinical study titled "A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris". Psoriasis is a common skin disease affecting an estimated 2.6% of the US population. It is a chronic, recurrent condition for which there is no cure, but there are ways to control it. Psoriasis is characterized by epidermal hyperplasia (abnormal increase in the number of normal cells of the outer la...
What is the current status of trial NCT00113542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2004-06. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00113542?
The interventions under investigation include: Tetrathiomolybdate (TM) (DRUG).
Who is sponsoring clinical trial NCT00113542?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.